検索結果

千寿製薬について | 千寿製薬株式会社

CEO Message Management Policy Company Profile Our Initiatives for Society / Environment Business Activities Production system Quality policy

临床试验信息 | 研究与开发 | 千寿制药株式会社

d jRCT2031210280 Disclaimer This website provides information on clinical trials sponsored by SENJU PHARMACEUTICAL Co., Ltd. (hereinafter referred to as “SENJU”) to the public including patients and t...

お知らせ | 千寿製薬株式会社

June 1, 2026 Launch of Distribution of 3in1Smart and SPM-700（PDF） April 6, 2026 Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition（

R&D Pipeline | Research & Development | SENJU Pharmaceutica

PROGRESS OF DEVELOPMENT Disclosuring of information after Phase 1 DrugIndicationStatus (Region) SJP-0132Dry eyeLaunched（Japan） PranoprofeninflammationApplication under review (Vietnam) SJP-0132Dry eye

点眼剤 (1％、2％) <A> イタリア Carteol S.I.F.I. S.p.A. 1988年 点眼剤 (1％、2％) <B> 香港 Arteoptic Otsuka Pharmaceutical (H.K.) Ltd. 1995 年 点眼剤 (1％、2％) <C> 台湾 Arteoptic TAIWAN OTSUKA PHARMACEUTICAL CO...